Truist raised the firm’s price target on Phreesia (PHR) to $34 from $31 and keeps a Buy rating on the shares after its Q3 results. The company notes that its EBITDA growth is not being driven by cost-cutting measures but rather harvesting significant upfront investments which were made a few years ago, the analyst tells investors in a research note. The firm further notes that Phreesia is guiding for its adjusted EBITDA margin expansion much faster than it had been anticipating, Truist states.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia price target lowered to $30 from $34 at Baird
- Phreesia’s Global Expansion: Navigating Legal Hurdles and Compliance Costs
- Phreesia Reports Strong Q3 2025 Performance
- Phreesia jumps 6% to $22.83 after Q3 results, updated guidance
- Phreesia narrows FY25 revenue view to $418M-$420M, consensus $419.1M